



EXCLUSIVE COLLABORATION AGREEMENT EXECUTED WITH MAJOR COSMETIC AND FRAGRANCE COMPANY

OBJ Limited (ASX: OBJ) ("OBJ") is pleased to announce that it has entered into an Exclusive Collaboration Agreement ("Agreement") with Philosophy, a skin care brand of COTY Inc., an emerging leader in beauty. The Agreement details the exploration of possible future development and manufacture of OBJ's patented *eSkin* system.

COTY Inc. markets a portfolio of widely known brands in fragrance, color cosmetics, and skin and body care products. COTY Inc. is active in 130 countries with manufacturing and research and development centres spread across a number of locations internationally. Philosophy was acquired by COTY Inc. in 2010 as its prestige skincare brand and now ranks in the top 10 skincare brands worldwide.

The Agreement defines the terms upon which OBJ and Philosophy will collaborate to develop, program and manufacture *eSkin* systems with the proprietary delivery fields necessary to control a number of key ingredients used widely by Philosophy.

The recent allowance of the Dermaportation patent by the European Patent Office and the granting of the same patent by the US Patent Office in 2012 are fundamental to the collaboration. The more recent filings of patent applications with the US and European patent offices over a number of key innovations that make up the *eSkin* system, add significantly to the overall strength of the *eSkin* IP.

For more information:

Mr Glyn Denison	Director	Telephone	+618 9443 3011
		Email	info@obj.com.au
		Web	www.obj.com.au

About OBJ:

OBJ develops proprietary magnetic micro-array drug delivery and product enhancement technologies for the pharmaceutical, healthcare and consumer goods sectors.

OBJ partners companies in the design and development of next generation products using physical science rather than chemistry to provide new levels of product performance without the cost of reformulation or new ingredient approvals.



OBJ offers a portfolio of proprietary technologies and supports partners by providing IP-protected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production.

About OBJ's Technologies

OBJ has developed a platform of physical enhancement technologies based on low-cost magnetic micro-arrays that influence the movement and penetration of drugs, active ingredients and formulations at the molecular level.

Complex 3-D array and moving magnetic fields have the ability to repulse certain molecules to enhance diffusion and to alter the permeability of certain biological and non-biological targets.

OBJ develops low cost micro-array film technology that utilises diamagnetic repulsion, induced permeation and energy redirection to offer a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical and consumer products.

Forward-looking Statements

This announcement contains certain "forward-looking statements" concerning OBJ. Where OBJ expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis.

Forward-looking statements provided in this announcement are based on assumptions and contingencies which are subject to change without notice. Such forward-looking statements including statements regarding intentions, planned events and potential results are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

There can be no assurance that actual outcomes will not differ materially from these forward-looking statements, and there are risks associated with OBJ and the industry which may affect the accuracy of the forward-looking statements. OBJ does not undertake any obligation to release publicly any revisions to any forward looking statement to reflect events or circumstances after the date of this announcement or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.